Clinical Trials Logo

Neuroendocrine Neoplasm clinical trials

View clinical trials related to Neuroendocrine Neoplasm.

Filter by:

NCT ID: NCT04459273 Recruiting - Clinical trials for Hepatocellular Carcinoma

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

FAPI PET RDRC
Start date: August 27, 2020
Phase: Phase 1
Study type: Interventional

This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.

NCT ID: NCT03734913 Recruiting - Glioblastoma Clinical Trials

A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors

Start date: January 25, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1602 in participants with basal cell carcinoma, adenocarcinoma of esophagogastric junction, small cell lung cancer, neuroendocrine neoplasm and other advanced solid tumors.

NCT ID: NCT03511768 Recruiting - Clinical trials for Neuroendocrine Neoplasm

A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

Start date: January 2, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide(18F-AlF-NOTA-octreotide ) positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).

NCT ID: NCT02817945 Recruiting - Lung Cancer Clinical Trials

Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging

Start date: June 1, 2016
Phase: Early Phase 1
Study type: Interventional

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluate the efficacy of 68Ga-NOTA-3PTATE-RGD in lung cancer patients and neuroendocrine neoplam patients. A single dose of 111-185 Mega-Becquerel (MBq) 68Ga-NOTA-3P-TATE-RGD will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

NCT ID: NCT02402244 Recruiting - Clinical trials for Malignant Solid Neoplasm

Project: Every Child for Younger Patients With Cancer

Start date: November 3, 2015
Phase:
Study type: Observational

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.